← All trials
NCT00366977
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2000
- Primary completion
- Jan 1, 2005
- Completion date
- Jan 1, 2005
- First posted
- —
- Last posted
- —
- Enrollment
- 4614
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- Kaiser PermanenteLead sponsor
- Oregon Health Division/Center for Disease Prevention EpidemiologyOverall official - principal investigator
- Kaiser PermanenteOverall official - principal investigator
- National Cancer Institute (NCI)Collaborator
- Group Health CooperativeCollaborator
- Department of Human Services, OregonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.